Mandate

Vinge advises Surgical Science in conjunction with a directed new issue of shares valued at SEK 2.7 billion

Surgical Science Sweden AB, listed on Nasdaq First North Growth Market, has performed a directed new issue of shares valued at approximately SEK 2.7 billion at a subscription price of SEK 210.

The subscription price was established through a so-called accelerated book building procedure arranged by Pareto Securities. The net proceeds from the directed issue of shares will primarily be used to finance the acquisition of Simbionix USA Corp which was made public on the same day as the directed new issue of shares. 

Vinge’s team consisted of Anders Strid, Edin Agic (project manager) and Adrian Filipovic.

 

 

Related

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024